Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction.
about
What is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single-centre cohort.Antinuclear Antibodies in Patients with Psoriatic Arthritis Treated or Not with Biologics.Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study.Impact of Renal Impairment on the Pharmacokinetics of Apremilast and Metabolite M12.Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA.A systematic review of biologics for the treatment of noninfectious uveitis.Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study.Drug-induced lupus and autoimmune hepatitis secondary to infliximab for psoriasis.Antidrug antibodies in psoriasis: a systematic review.Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response.Systematic review of infliximab-induced autoantibodies and systemic lupus erythematosus.Emergence of antinuclear antibodies in psoriatic patients treated with infliximab: personal experience and literature review.Long-term study of infliximab for psoriasis in daily practice: drug survival depends on combined treatment, obesity and infusion reactions.Immunogenicity of biologic treatments for psoriasis: therapeutic consequences and the potential value of concomitant methotrexate.Practical guidance on immunogenicity to biologic agents used in the treatment of psoriasis: What can be learnt from other diseases?Recommendations for managing a suboptimal response to biologics for moderate-to-severe psoriasis: A Belgian perspective.Observational case series on a group of psoriasis patients who failed to respond to any TNF blockers.Singapore Chapter of Rheumatologists consensus statement on the eligibility for government subsidy of biologic disease modifying anti-rheumatic agents for the treatment of psoriatic arthritis.Long persistence of tumour necrosis factor-α antagonist-induced autoantibodies under subsequent treatment with ustekinumab but no adverse effects: a case study of 14 patients with psoriasis.Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab.Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far.Increased circulating follicular helper T cells and activated B cells correlate with disease severity in patients with psoriasis.Updates from the British Association of Dermatologists 91st annual meeting, 5-7 July 2011, London, U.K.
P2860
Q30826279-ED8FDB43-0685-4742-B7BE-3AA81B801E44Q35731234-9EA49960-92DE-47BB-9ED4-62A832EB5CA4Q35907845-D73FA82F-2676-4347-B951-DA5808D0FDDBQ37462071-CDB70E8E-EFAA-4D9F-92A0-3161DA674E54Q37599165-93DD46BC-8885-4C2E-9BF5-1453F093F3B5Q38068969-4BD5DE39-17B7-4D5A-AE23-B4CD49FC59E7Q38095548-BE3F8663-677E-4189-B6D2-1B8D9EAF218FQ38104769-E16B1954-6AEC-464C-A562-5EC9336BFBF0Q38151757-4C63FAB1-9D4E-4B5E-8D00-94B1D8B5E9DAQ38152820-D0B2F72D-CE14-4658-B2FC-1A72D4E5F6A0Q38161813-35293BD4-DE55-4868-82D9-A4A647BA6C75Q38266321-BEF922D9-B418-4F5F-8346-55254CD15D83Q38286010-960EF579-5189-4C4A-9844-42549018310FQ38473460-0A30CE7D-9D3B-4D7F-80CC-32E696D54D76Q38537167-F0EE5C19-C378-411D-AB3B-A943627335A7Q38594683-3D5EB929-B439-4C85-9570-20229FB82118Q43613356-2679B02F-A77F-41B3-8E0F-2975E62C0788Q46129663-563E0129-6927-4C87-9A37-D0A0B938B2F1Q48329258-28644B71-5CD2-49CC-97CA-9D9BEEEE66A7Q50065301-ADDF6824-1E65-486A-895E-7E6C7E8771C0Q50083992-43CA5DDF-BB30-41AC-BC57-5ED79B105DB5Q50749843-11688F48-209E-42E9-816E-EFE9C6FA52AEQ51189512-CDCA10C1-9C6F-4071-AA4E-1E01E4FD4D6B
P2860
Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Autoantibodies in psoriasis as ...... infliximab antibody induction.
@en
Autoantibodies in psoriasis as ...... infliximab antibody induction.
@nl
type
label
Autoantibodies in psoriasis as ...... infliximab antibody induction.
@en
Autoantibodies in psoriasis as ...... infliximab antibody induction.
@nl
prefLabel
Autoantibodies in psoriasis as ...... infliximab antibody induction.
@en
Autoantibodies in psoriasis as ...... infliximab antibody induction.
@nl
P2093
P2860
P1476
Autoantibodies in psoriasis as ...... -infliximab antibody induction
@en
P2093
E N Hadaschik
M Hartmann
P2860
P304
P356
10.1111/J.1365-2133.2011.10555.X
P407
P577
2011-11-17T00:00:00Z